- Home
- LMB vs VTYX Comparison
LMB vs VTYX Comparison
Compare LMB & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LMB | VTYX |
|---|---|---|
| Founded | 1901 | 2018 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Engineering & Construction | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 990.9M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LMB | VTYX |
|---|---|---|
| Price | $81.08 | $13.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 7 |
| Target Price | ★ $130.00 | $13.50 |
| AVG Volume (30 Days) | 157.1K | ★ 3.4M |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.68 | ★ 40.30 |
| EPS | ★ 3.23 | N/A |
| Revenue | ★ $646,804,000.00 | N/A |
| Revenue This Year | $16.50 | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | $25.02 | ★ N/A |
| Revenue Growth | ★ 24.68 | N/A |
| 52 Week Low | $63.02 | $0.90 |
| 52 Week High | $154.04 | $15.34 |
Technical Indicators
Market Signals| Indicator | LMB | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 72.58 |
| Support Level | $77.96 | $13.89 |
| Resistance Level | $85.30 | $14.07 |
| Average True Range (ATR) | 6.63 | 0.03 |
| MACD | -1.66 | -0.11 |
| Stochastic Oscillator | 11.78 | 88.89 |
Price Performance
Historical ComparisonAbout LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.